RxDoctor Payments DataLook up a doctor →

Toby Rogers

Interventional Cardiology · Washington, DCNPI 1548625908

Payments from drug & device makers

$978,420in general payments, 2019–2025

Across 1,113 payments — averaging $879.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$453K
  • Edwards Lifesciences$415K
  • Abbott$83K
  • Boston Scientific$21K
  • Jenavalve Technology, Inc.$1K
  • Ancora Heart, Inc.$1K
  • plus $4K from 22 others
$24,200in research payments, 2019–2025

Across 29 payments — averaging $834.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$24K

What the payments were for

  • Consulting fees$445,26251%
  • Speaking & faculty fees$301,39734%
  • Travel & lodging$109,49412%
  • Food & beverage$23,6793%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$128,177
Medicare patients
280
Services billed
394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate15$62

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →